Pharmaceutical Contract Manufacturing World Market To Reach $79.24bn In 2019

LONDON - March 4, 2015 - PRLog -- London, UK, 10^th of February 2015:

A new report by visiongain (http://www.visiongain.com/) forecasts the world market for pharma (http://www.visiongain.com/Sector/8/Pharma) contract manufacturing will generate $79.24bn in 2019. Contract active pharmaceutical ingredient (API) and finished dosage formulation (FDF) manufacturing will experience strong revenue growth in the first half of the 2013-2025 forecasting period. Although generic APIs will remain as the main contributor in that production services industry, demand for highly potent APIs (HPAPIs) will increase in this forecast period, with a revenue growth CAGR of 7.7%. Those predictions and others appear in Pharmaceutical Contract Manufacturing: World Industry and Market Outlook 2015-2025 (https://www.visiongain.com/Report/1396/Pharmaceutical-Contract-Manufacturing-World-Industry-and-Market-Outlook-2015-2025), published in February 2015.

The purpose of that study is to give business forecasting that planners, influencers and leaders need. Visiongain is a business information publisher and consultancy in London, UK. It produces analysis to help companies understand industries and their potentials.

That new investigation finds API manufacturing services accounted for the largest proportion of contract manufacturing organisation (CMO) revenue in 2014. This will continue to be the case throughout the period 2015-2025. Demand will be strong for highly potent APIs in developed national markets. That trend encourages CMOs to invest in upgrading their facilities to offer manufacturing capacity in HPAPIs. Fastest growth in the worldwide contract manufacturing market will come from the contract FDF manufacturing sector. That submarket’s revenues will grow with a CAGR of 6.8% between 2013 and 2025, the study finds.

Sandra Wenas, a pharmaceutical industry analyst in visiongain, said: “The pharmaceutical contract manufacturing industry will continue to achieve consolidation via mergers and acquisitions (M&A). Consolidation is expected to peak in the next five years, as more CMOs strive to provide a one-stop-shop, offering services from APIs to finished doses. Excess capacity is also the driver of the recent M&A activities.

“Affordability is no longer the main parameter in selecting CMOs for partnership, as sponsor companies will increasingly emphasize quality, compliance with regulatory demands and service requirements. Technological advances will also stimulate that market from 2015 to 2025. Also CMOs invest in single-use technologies for biopharmaceutical manufacturing and continuous manufacturing processes. CMOs will also invest heavily to expand their capacities in HPAPIs.”

Along with prediction of the overall world market for outsourced drug production, visiongain’s new report gives revenue forecasting of 11 world-level submarkets to 2025:

Active pharmaceutical ingredients (APIs), with sub forecasts for generic APIs, high potency active pharma ingredients (HPAPIs) and other products
Finished dosage formulations (FDFs), with sub forecasts for solid dose forms, injectable dosages, and other agents
Other applications of outsourced production
Clinical manufacturing
Commercial manufacturing.

In 2015 commercial manufacturing projects account for most CMO revenue. However, improved funding for early-stage projects in the US and EU will drive demand for clinical trial material manufacturing towards the middle of the forecast period. The growing R&D pipeline of novel antibody-drug conjugates (ADCs) will also create more opportunities for CMOs offering specialised manufacturing technologies, further stimulating the market.

Visiongain’s new study also discusses regulatory developments and demand for pharma contract manufacturing services in leading and emerging national markets. That work analyses the US, Japan, Germany, France, Italy, Spain, the UK, China, India, Brazil, Russia and South Korea, with revenue forecasting to 2025. Developed markets account for the greatest demand for outsourced drug manufacturing. The US and EU accounted for 63.9% of CMO revenues in 2013. And concerns with regulatory compliance led some Western companies to seek outsourcing partners closer to home. Emerging national markets, however, will still generate much business from pharma companies wanting custom medicine production.

That investigation provides quantitative and qualitative analyses of the pharma contract manufacturing market for the period 2015 to 2025. It also shows interviews with companies.Pharmaceutical Contract Manufacturing: World Industry and Market Outlook 2015-2025 adds to visiongain’s portfolio of market analyses on pharmaceutical outsourcing and other healthcare industries.

For sample pages and further information concerning the visiongain report Pharmaceutical Contract Manufacturing: World Industry and Market Outlook 2015-2025 please visithttps://www.visiongain.com/Report/1396/Pharmaceutical-Contract-Manufacturing-World-Industry-and-Market-Outlook-2015-2025

For an executive summary please contact:
Email: Sara Peerun on sara.peerun@visiongainglobal.com

Tel: +44 (0) 20 7336 6100

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail tosara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain

Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. From its head office in London, UK, visiongain produces a range of newsletters, business reports and e-zines covering current affairs and market trends in the Energy, Telecoms, Pharmaceutical, Defence, and Materials sectors.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high quality, original analyses to inform their strategic decisions.